8/7/2008

Tolerx started a late-stage clinical study of otelixizumab that involves 240 adults with new-onset Type 1 diabetes. The biopharmaceutical firm will receive $15 million in a milestone payment from partner GlaxoSmithKline for the study, which is being conducted in North America and Europe.

Related Summaries